Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.41 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KLK7 | P49862 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | CCR3 | P51677 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8510456 | 0.76 | GPR119 (0.39) | GPR119 | |
| SCHEMBL2724153 | 0.76 | USP30 (0.43) | KDM1AGPR119 | |
| SCHEMBL2707640 | 0.75 | BACE1 (0.41) | BACE1BACE2DDB1CRBNKLK7 | |
| SCHEMBL9611358 | 0.75 | BACE1 (0.41) | BACE1BACE2DDB1CRBNKLK7 | |
| SCHEMBL22047155 | 0.73 | BACE1 (0.43) | BACE1BACE2S1PR5DDB1CRBN | |
| SCHEMBL21996478 | 0.73 | BACE1 (0.43) | BACE1BACE2S1PR5DDB1CRBN | |
| SCHEMBL8514291 | 0.73 | DPP8 (0.39) | BACE1BACE2POLBNPC1RAB9A | |
| SCHEMBL4050280 | 0.73 | CHRM2 (0.35) | DDB1CRBNPOLBKDM1AGPR119 | |
| SCHEMBL5941747 | 0.73 | CHRM2 (0.35) | DDB1CRBNPOLBKDM1AGPR119 | |
| SCHEMBL16434872 | 0.73 | BACE1 (0.49) | BACE1BACE2DDB1CRBNKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415486-B2 | IAP inhibitors | TETRALOGIC PHARMACEUTICALS CORP. (US) | 2013-04-09 | — | — | US | disclosed |
| US-20120135990-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP. (US) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135990-A1 | IAP INHIBITORS | XIAP, IAPP, BIRC5 | BACE1 33/4885BACE2 41/4885S1PR5 3852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.